Antibody Information
General Information of This Antibody (ID: ANTI0FOSFI)
| Antibody Name | Anti-human BCMA IgG1 mAb |
|||||
|---|---|---|---|---|---|---|
| Antigen Name | BCMA |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
AMG 224 [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | stable disease (SD) |
30%
|
|||
| Patients Enrolled |
Eligibility required relapsed/refractory MM after ≥3 prior lines (including PI+IMiD), measurable disease per IMWG, and adequate hematologic/organ function (ANC ≥1.0×10^9/L, platelets ≥50-75×10^9/L, LVEF >50%). Excluded: plasma cell leukemia/POMS/Waldenström's, recent SCT (<90 days), QTc >470ms, active CHF (NYHA class III/IV), or anti-tumor therapy within 28 days. Concurrent prednisone ≤30mg/day was permitted.
Click to Show/Hide
|
||||
| Administration Dosage |
In the dose escalation, patients received intravenous AMG 224 every 3 weeks (Q3W) at prespecified doses of 30-300 mg in a 3 + 3 design, with no mandated premedications.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02561962 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma
|
||||
| Primary Endpoint |
Dose-limiting toxicities (DLTs) were assessed during the first 28 days using CTCAE v4.0, defining hematologic DLTs as prolonged grade 4 cytopenias (neutropenia >7 days, thrombocytopenia >7 days) or grade 3+ cytopenias with complications (fever/hemorrhage), and non-hematologic DLTs as grade 3+ organ toxicities (liver/kidney), persistent GI toxicity >3 days despite therapy, or cases meeting Hy's Law criteria. Treatment-emergent AEs were monitored through Cycle 4 (12 weeks) including vital signs, labs, and neurologic assessments.
Click to Show/Hide
|
||||
| Other Endpoint |
PK parameters (Cmax, Cmin, AUC, clearance, t1/2) of AMG 224's antibody-drug conjugate (anti-BCMA-MCC-DM1) components were assessed in Cycles 1-2. Efficacy outcomes included best overall response per IMWG-URC (CR/sCR/VGPR/PR), time-to-progression, duration of response (Kaplan-Meier), MRD-negativity rate (sensitivity <1:10^5), and immunogenicity (anti-drug antibodies) over 6 years. Intensive PK sampling occurred pre/post-infusion through 336 hours.
Click to Show/Hide
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | progressive disease (PD) |
15%
|
|||
| Patients Enrolled |
Eligibility required relapsed/refractory MM after ≥3 prior lines (including PI+IMiD), measurable disease per IMWG, and adequate hematologic/organ function (ANC ≥1.0×10^9/L, platelets ≥50-75×10^9/L, LVEF >50%). Excluded: plasma cell leukemia/POMS/Waldenström's, recent SCT (<90 days), QTc >470ms, active CHF (NYHA class III/IV), or anti-tumor therapy within 28 days. Concurrent prednisone ≤30mg/day was permitted.
Click to Show/Hide
|
||||
| Administration Dosage |
In the dose escalation, patients received intravenous AMG 224 every 3 weeks (Q3W) at prespecified doses of 30-300 mg in a 3 + 3 design, with no mandated premedications.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02561962 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma
|
||||
| Primary Endpoint |
Dose-limiting toxicities (DLTs) were assessed during the first 28 days using CTCAE v4.0, defining hematologic DLTs as prolonged grade 4 cytopenias (neutropenia >7 days, thrombocytopenia >7 days) or grade 3+ cytopenias with complications (fever/hemorrhage), and non-hematologic DLTs as grade 3+ organ toxicities (liver/kidney), persistent GI toxicity >3 days despite therapy, or cases meeting Hy's Law criteria. Treatment-emergent AEs were monitored through Cycle 4 (12 weeks) including vital signs, labs, and neurologic assessments.
Click to Show/Hide
|
||||
| Other Endpoint |
PK parameters (Cmax, Cmin, AUC, clearance, t1/2) of AMG 224's antibody-drug conjugate (anti-BCMA-MCC-DM1) components were assessed in Cycles 1-2. Efficacy outcomes included best overall response per IMWG-URC (CR/sCR/VGPR/PR), time-to-progression, duration of response (Kaplan-Meier), MRD-negativity rate (sensitivity <1:10^5), and immunogenicity (anti-drug antibodies) over 6 years. Intensive PK sampling occurred pre/post-infusion through 336 hours.
Click to Show/Hide
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Partial Response (PR) |
13%
|
|||
| Patients Enrolled |
Eligibility required relapsed/refractory MM after ≥3 prior lines (including PI+IMiD), measurable disease per IMWG, and adequate hematologic/organ function (ANC ≥1.0×10^9/L, platelets ≥50-75×10^9/L, LVEF >50%). Excluded: plasma cell leukemia/POMS/Waldenström's, recent SCT (<90 days), QTc >470ms, active CHF (NYHA class III/IV), or anti-tumor therapy within 28 days. Concurrent prednisone ≤30mg/day was permitted.
Click to Show/Hide
|
||||
| Administration Dosage |
In the dose escalation, patients received intravenous AMG 224 every 3 weeks (Q3W) at prespecified doses of 30-300 mg in a 3 + 3 design, with no mandated premedications.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02561962 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma
|
||||
| Primary Endpoint |
Dose-limiting toxicities (DLTs) were assessed during the first 28 days using CTCAE v4.0, defining hematologic DLTs as prolonged grade 4 cytopenias (neutropenia >7 days, thrombocytopenia >7 days) or grade 3+ cytopenias with complications (fever/hemorrhage), and non-hematologic DLTs as grade 3+ organ toxicities (liver/kidney), persistent GI toxicity >3 days despite therapy, or cases meeting Hy's Law criteria. Treatment-emergent AEs were monitored through Cycle 4 (12 weeks) including vital signs, labs, and neurologic assessments.
Click to Show/Hide
|
||||
| Other Endpoint |
PK parameters (Cmax, Cmin, AUC, clearance, t1/2) of AMG 224's antibody-drug conjugate (anti-BCMA-MCC-DM1) components were assessed in Cycles 1-2. Efficacy outcomes included best overall response per IMWG-URC (CR/sCR/VGPR/PR), time-to-progression, duration of response (Kaplan-Meier), MRD-negativity rate (sensitivity <1:10^5), and immunogenicity (anti-drug antibodies) over 6 years. Intensive PK sampling occurred pre/post-infusion through 336 hours.
Click to Show/Hide
|
||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
23%
|
|||
| Patients Enrolled |
Eligibility required relapsed/refractory MM after ≥3 prior lines (including PI+IMiD), measurable disease per IMWG, and adequate hematologic/organ function (ANC ≥1.0×10^9/L, platelets ≥50-75×10^9/L, LVEF >50%). Excluded: plasma cell leukemia/POMS/Waldenström's, recent SCT (<90 days), QTc >470ms, active CHF (NYHA class III/IV), or anti-tumor therapy within 28 days. Concurrent prednisone ≤30mg/day was permitted.
Click to Show/Hide
|
||||
| Administration Dosage |
In the dose escalation, patients received intravenous AMG 224 every 3 weeks (Q3W) at prespecified doses of 30-300 mg in a 3 + 3 design, with no mandated premedications.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02561962 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma
|
||||
| Primary Endpoint |
Dose-limiting toxicities (DLTs) were assessed during the first 28 days using CTCAE v4.0, defining hematologic DLTs as prolonged grade 4 cytopenias (neutropenia >7 days, thrombocytopenia >7 days) or grade 3+ cytopenias with complications (fever/hemorrhage), and non-hematologic DLTs as grade 3+ organ toxicities (liver/kidney), persistent GI toxicity >3 days despite therapy, or cases meeting Hy's Law criteria. Treatment-emergent AEs were monitored through Cycle 4 (12 weeks) including vital signs, labs, and neurologic assessments.
Click to Show/Hide
|
||||
| Other Endpoint |
PK parameters (Cmax, Cmin, AUC, clearance, t1/2) of AMG 224's antibody-drug conjugate (anti-BCMA-MCC-DM1) components were assessed in Cycles 1-2. Efficacy outcomes included best overall response per IMWG-URC (CR/sCR/VGPR/PR), time-to-progression, duration of response (Kaplan-Meier), MRD-negativity rate (sensitivity <1:10^5), and immunogenicity (anti-drug antibodies) over 6 years. Intensive PK sampling occurred pre/post-infusion through 336 hours.
Click to Show/Hide
|
||||
| Experiment 5 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
23.00
60.00 % |
|||
| Patients Enrolled |
Relapsed or refractory (R/R) multiple myeloma (MM).
|
||||
| Administration Dosage |
Every 3 weeks (Q3W) at prespecified doses of 30-300 mg in a 3+3 design.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02561962 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 first in human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 224 in subjects with relapsed or refractory multiple myeloma.
|
||||
| Primary Endpoint |
AmG 224 was generally well tolerated up to 190 mg Q3W.
|
||||
| Other Endpoint |
ORR=23.00% (95% CI,11.00-39.00%), including six responses in dose escalation and three responses in the dose expansion. Two (5.00%) patients were CR and 7 (18.00%) patients were PR.
|
||||
| Experiment 6 Reporting the Activity Date of This ADC | [3] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT02561962 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 first in human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 224 in subjects with relapsed or refractory multiple myeloma.
|
||||
References